8-K: Iridex Reports Q2 2025 Growth, Achieves Positive EBITDA

Iridex Corporation announced its second quarter 2025 financial results, reporting revenue growth and achieving positive non-GAAP adjusted EBITDA for the third consecutive quarter.

Summary

• Total revenue for Q2 2025 was $13.6 million, a 7% increase year-over-year and 14% sequential growth from Q1 2025.
• Cyclo G6 product family revenue was $3.3 million, flat year-over-year, with 13,100 probes sold (down from 15,100) and 35 Cyclo G6 Glaucoma Laser Systems sold (up from 28).
• Retina product revenue grew 10% year-over-year to $8.0 million, and 21% sequentially.
• Operating expenses were reduced by 28% to $5.6 million compared to $7.8 million in Q2 2024, primarily due to expense reduction measures taken in late 2024.
• Net loss significantly improved to $1.0 million ($0.06 per share) in Q2 2025, down from $2.7 million ($0.16 per share) in Q2 2024.
• Achieved positive non-GAAP adjusted EBITDA of $21 thousand in Q2 2025, an improvement of $1.7 million from a $1.7 million loss in Q2 2024, marking the third consecutive quarter of positive adjusted EBITDA.
• Cash and cash equivalents stood at $6.8 million as of June 28, 2025, a reduction of $0.4 million during the quarter.

Sentiment

Score: 7

Explanation: The company shows strong positive momentum in profitability metrics (EBITDA, net loss reduction) and effective cost control, despite mixed revenue performance in specific product lines and a slight cash reduction in the quarter. The overall narrative from management is one of successful 'transformational progress' towards a self-sustaining business.

Positives

• Achieved 7% year-over-year revenue growth and 14% sequential growth in Q2 2025, driven by higher Pascal system sales and medical/surgical retina system sales.
• Successfully reduced operating expenses by 28% year-over-year, demonstrating effective cost management.
• Reported positive non-GAAP adjusted EBITDA of $21 thousand for the third consecutive quarter, indicating a strong trend towards profitability.
• Significantly narrowed net loss to $1.0 million ($0.06 per share) from $2.7 million ($0.16 per share) in the prior year quarter.
• Increased sales of Cyclo G6 Glaucoma Laser Systems to 35 units from 28 units year-over-year.

Negatives

• Gross profit decreased by $0.4 million to $4.7 million, with gross margin declining to 34.5% from 40.7% in Q2 2024.
• Gross margin decline was attributed to increased manufacturing costs, product mix favoring capital system sales, and geographic mix favoring international sales.
• Cyclo G6 probe sales decreased to 13,100 from 15,100 in the prior year quarter.
• Cash and cash equivalents decreased by $0.4 million during the quarter.

Risks

• Forward-looking statements are not guarantees of future performance, and actual results may differ materially due to various factors.
• Detailed descriptions of risks are available in the Risk Factors section of the most recent Annual Report on Form 10-K and other reports filed with the SEC.

Future Outlook

The company plans to achieve cash flow breakeven and positive adjusted EBITDA in 2025, with revenue generation consistent with 2024. Management is focused on identifying and executing additional opportunities to lower expenses and improve margins to build a financially disciplined, self-sustaining business.

Management Comments

• "Our second quarter results represent the transformational progress we are making on refocusing our business model to drive toward profitability."
• "For the third consecutive quarter, we have achieved year-over-year revenue growth, reduced operating expenses, and delivered breakeven or better adjusted EBITDA."
• "We continue to identify and execute on additional opportunities to lower expenses further and improve margins."
• "We remain focused and committed to take the necessary steps to build a more financially disciplined self-sustaining business, while strengthening our competitive position in the market."

Industry Context

Iridex operates in the ophthalmology market, specializing in laser-based medical systems for glaucoma and retinal diseases. The reported results indicate a strategic shift towards profitability through cost reduction and focused growth in key product areas like retina systems, aligning with broader trends of efficiency and specialized innovation in the medical device sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. However, achieving positive adjusted EBITDA for three consecutive quarters, coupled with significant operating expense reductions, suggests a strong internal turnaround effort compared to its own historical performance.

Stakeholder Impact

• Shareholders: Potential positive impact due to improved profitability, reduced net loss, and a clear path towards a self-sustaining business, though diluted by a capital raise.
• Employees: Impacted by expense reduction measures taken in late 2024, which contributed to lower operating expenses.
• Customers: Continued access to innovative laser-based medical systems for glaucoma and retinal diseases, with growth in retina product revenue and Pascal system sales.

Next Steps

• Host a conference call on August 12, 2025, at 2:00 p.m. PT / 5:00 p.m. ET to discuss financial results.
• Continue to identify and execute on additional opportunities to lower expenses and improve margins.
• Work towards achieving cash flow breakeven and positive adjusted EBITDA for the full year 2025.

Key Dates

Recommendation

Iridex Corporation demonstrates significant operational improvements, evidenced by a 28% reduction in operating expenses, a substantial narrowing of net loss, and achieving positive non-GAAP adjusted EBITDA for three consecutive quarters. This indicates a successful turnaround in profitability. While there are mixed revenue details (e.g., decline in G6 probes), the overall trajectory towards a 'self-sustaining business' is strong. The increase in long-term convertible notes suggests successful capital securing to support this transformation. For an investor seeking a company with clear signs of operational efficiency and a path to sustained profitability, this filing presents a compelling 'buy' opportunity.

Keywords

Iridex, IRIX, Ophthalmology, Glaucoma, Retinal Diseases, Laser Systems, Medical Devices, Financial Results, Earnings, EBITDA, Revenue Growth, Operating Expenses